GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...

The prescribed dosage for Nucala (mepolizumab) may vary depending on a person’s individual treatment plan, specific diagnosis, and age. Typically, Nucala is given once every 4 weeks as a ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

The data suggest that Nucala could offer a meaningful benefit to those in need of additional treatments to reduce exacerbation risks. If approved, Nucala would be the first biologic with monthly ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

Submission based on data from MATINEE trial, which showed a significant and clinically meaningful reduction in rate of moderate/severe exacerbations with Nucala compared to placebo · Data ...

The data suggest that Nucala could offer a meaningful benefit to those in need of additional treatments to reduce exacerbation risks. If approved, Nucala would be the first biologic with monthly ...